A study published on December 11th in PLOS Pathogens reports that genetic variants in a gene called IL - 28B influence
influenza vaccine responses.
Not exact matches
This insight may help us improve
vaccine responses in the elderly — a group at particular risk of diseases including
influenza — by pre-treatment with anti-inflammatory agents.»
In collaboration with many researchers (graduate students, postdocs, and faculty elsewhere), we have examined the role of cross-immunity on the evolution and dynamics of
influenza; the impact of behavioral changes, long periods of infectiousness, variable infectivity, co-infections, prostitution, social networks, and
vaccine efficacy on HIV dynamics; the role of exogenous re-infection, variable progression rates, vaccination, public transportation, close and casual contacts on tuberculosis dynamics and control; the impact of life - history vector dynamics on dengue epidemics; and on the identification of time -
response scales for epidemics of foot and mouth disease.
A team led by Ron Dagan, a pediatric infectious disease specialist at Soroka University Medical Center in Beer - Sheva, Israel, wanted to know if a new pneumococcal
vaccine based on tetanus toxoid would change infants» immune
responses to the standard regimen of
vaccines, including those for diphtheria, tetanus, pertussis (DTP), and Haemophilus
influenzae type B, which protects against meningitis.
Back to the future: Immunization with M - 001 prior to trivalent
influenza vaccine in 2011/12 enhanced protective immune
responses against 2014/15 epidemic strain.
In a phase 2 trial that included nearly 1,000 adults, the AS03 and MF59 adjuvants (a component that improves immune
response of inactivated
influenza vaccines) increased the immune
responses to two doses of an inactivated H7N9
influenza vaccine, with AS03 - adjuvanted formulations inducing the highest amount of antibody
response, according to a study in the July 21 issue of JAMA.
Researchers concluded that the high - dose
vaccine is safe, induces significantly higher antibody
responses, and provides superior protection against laboratory - confirmed
influenza illness compared to standard dose among persons over 65 years of age.
«The idea behind this study was to re-evaluate the bar that was previously established for evaluating a person's immune
response to
influenza vaccines,» said the study's principal investigator Matthew J. Memoli, M.D., director of the Clinical Studies Unit in NIAID's Laboratory of Infectious Diseases.
The
influenza specific T - follicular helper cell
response varied based on trimester of pregnancy in which the
vaccine was given.
Vaccine immunology is poorly understood in pregnancy and Tfh cell expansion has been shown to be a predictor of
response to
influenza vaccination outside of pregnancy.
No data are yet available for trials in children, who typically have much less robust immune
responses to the seasonal
influenza vaccine and require a second dose.
And when they pre-treated immune cells from vaccinated major allele carriers with a molecule that inhibits the receptor that is normally stimulated by IL - 28B, they saw a stronger antibody
response after the cells were stimulated with
influenza vaccine.
The study, published in the Journal of Infectious Diseases and funded by
vaccine - maker Sanofi Pasteur, found that — with the exception of one strain of flu circulating in the 2012 - 2013 season — the high dose flu
vaccine helped participants mount a better immune
response to
influenza than the standard flu shot.
The degree of splitting could influence how the
vaccine triggers an immune
response, said one
influenza vaccine expert who asked for anonymity.
The «primer» pandemic
influenza vaccine — made from live but weakened virus — introduces the immune system to H7N9
influenza virus, and subsequent vaccination with the «booster» inactivated virus
vaccine recalls a more robust immune
response.
«Careful consideration of the complexity of
influenza immune protection and evaluation of all aspects of the anti-
influenza immune
responses will ultimately be necessary in the development of a successful broadly protective or universal
influenza vaccine,» the authors said.
In clinical trials, several candidate H7N9 pandemic
influenza vaccines made from inactivated viruses have been shown to be safe and to generate an immune
response.
Beyond the issue of alleviating real and potential shortages of
influenza -
vaccine supplies is the possibility of pursuing vaccination strategies that would induce optimal immunity among populations of persons who not only are at greatest risk for complications but who also generally do not mount an optimal immune
response.
Specifically, 1 unit of access comprising a vaccination / challenge study with 3 groups of 6 ferrets (control and 2
vaccine groups), to include vaccination / boost, intra-nasal challenge with
influenza virus, monitoring of virus load (nasal washes), disease progression and immune
responses (antibody, IFN gamma ELISA and ELISpot).
Several candidate gene studies suggest that variations in HLA class 1 and other genes contribute to differences in antibody
response to
influenza vaccines [15], [69], [70].
A feasibility study: association between gut microbiota enterotype and antibody
response to seasonal trivalent
influenza vaccine in adults — Nick Shortt — Clinical and Translational Immunology
Genetic information about immune
response to
influenza could inform
vaccine development and distribution, and disease treatment strategies [17], [67], [68].
Prof. Sarah Gilbert: I am the author of a patent on an
influenza vaccine to induce broad immunity through T cell
responses
Previous studies have also indicated that maternal Abs did not suppress infant Ab
responses to H.
influenzae type B
vaccines (132).
«IL - 28B is a key regulator of B - and T - Cell
vaccine responses against
influenza» by Adrian Egli et al. published in PLOS Pathogens on Thursday 11 December 2014.
«The study by Egli et al. holds promise for enhancing the
response of the seasonal
influenza vaccine by blocking the receptor used for the innate immunity signalling molecule IL28B.
The unit of access comprises a vaccination / challenge study with 3 groups of 6 ferrets (control and 2
vaccine groups), to include intra-nasal challenge with
influenza virus, monitoring of virus load (nasal washes), disease progression and immune
responses (antibody, IFN gamma ELISA and ELISpot).
Kiecolt - Glaser JK, Glaser R, Gravenstein S, et al: Chronic stress alters the immune
response to
influenza virus
vaccine in older adults.
Effects of zinc supplementation on the immune system and on antibody
response to multivalent
influenza vaccine in hemodialysis patients.
Kitikoon P, Nilubol D, Vincent A, Yu S, Erickson B, Janke B, Hoover T, Sornsen S, Thacker E. Immune
response and effect of maternal antibody interference on vaccination with a bivalent swine
influenza vaccine.
Live attenuated
influenza vaccines have been shown to provide better immune
responses to protect against
influenza.
FLORHAM PARK, N.J., Sept. 9, 2014 — Zoetis has partnered with the renowned Gluck Equine Research Center at the University of Kentucky to show that FLUVAC INNOVATOR ®, the first equine
influenza virus (EIV)
vaccine, can provide a demonstrated cross-reactive immune
response against emerging EIV strains.
His current research interest at University of Rochester focuses on the molecular biology, pathogenesis, innate immune
responses and
vaccine development for RNA viruses, mainly arenaviruses and
influenza.
Evaluation of the ability of canarypox - vectored equine
influenza virus
vaccines to induce humoral immune
responses against canine
influenza viruses in dogs.
Guebre - Xabier, M., Hammond, S.A., Epperson, D.E., Yu, J., Ellingsworth, L., Glenn, G.M. Immunostimulant patch containing heat labile enterotoxin from E. coli enhances immune
responses to injected
influenza vaccine through activation of dendritic cells.
Researchers at the University of Birmingham in the United Kingdom, who studied married couples» antibody
response to an
influenza vaccine, found that people in satisfying marriages had stronger immunity to flu viruses.